(rac) -AR-13503

(rac) -AR-13503 ((rac) -AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C) . AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice[1][2].

Product Specifications

CAS Number

[1254032-16-0]

Product Name Alternative

(rac) -AR-13324 M1 metabolite

UNSPSC

12352005

Target

PKC; ROCK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rac-ar-13503.html

Purity

99.08

Solubility

1 M HCl : 25 mg/mL (ultrasonic) |DMSO : 40 mg/mL (ultrasonic; warming; adjust pH to 2 with 1 M HCl; heat to 60°C)

Smiles

O=C(C(CN)C1=CC=C(CO)C=C1)NC2=CC3=C(C=C2)C=NC=C3

Molecular Formula

C19H19N3O2

Molecular Weight

321.37

References & Citations

[1]Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 205-205. |[2]Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 200-200.